ANDA 76317, held by Teva. Topiramate.
As of Nov 15, 2026, ANDA 76317 (Topiramate), held by Teva, was first approved by FDA on Mar 27, 2009, with 9 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Mar 27, 2009 | Original application | Approved | None posted |
| Topiramate25MG · tablet;oral | Topiramate | Discontinued |
| Topiramate50MG · tablet;oral | Topiramate | Discontinued |
| Topiramate100MG · tablet;oral | Topiramate | Discontinued |
| Topiramate200MG · tablet;oral | Topiramate | Discontinued |
| Nov 17, 2014 | Supplement 10Labeling · Standard review | Approved | None posted |
| Nov 17, 2014 | Supplement 9Labeling · Standard review | Approved | None posted |
| Nov 17, 2014 | Supplement 8Labeling · Standard review | Approved | None posted |
| Nov 17, 2014 | Supplement 7Labeling · Standard review | Approved | None posted |
| Jun 17, 2011 | Supplement 6Labeling | Approved | None posted |
| Dec 23, 2010 | Supplement 4Labeling | Approved | None posted |
| Aug 13, 2010 | Supplement 3REMS | Approved | None posted |
| Jan 28, 2010 | Supplement 2Labeling | Approved | None posted |
| Jul 22, 2009 | Supplement 1Labeling | Approved | None posted |
| Mar 27, 2009 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters